Literature DB >> 11708407

Serum levels of interleukin 15 in patients with rheumatic diseases.

J Suzuki1, S Morimoto, H Amano, Y Tokano, Y Takasaki, H Hashimoto.   

Abstract

OBJECTIVE: The role of the cytokine interleukin 15 (IL-15) in rheumatic disease is unclear. We examined serum levels of IL-15 in patients with various rheumatic diseases.
METHODS: Serum levels of IL-15 were determined by sandwich ELISA.
RESULTS: Serum levels of IL-15 were significantly increased in patients with polymyositis/dermatomyositis, polyarteritis nodosa, and systemic sclerosis; and significantly increased as well in disease complicated by interstitial pneumonitis (IP), hemophagocytic syndrome (HPS), and/or vasculitis. Patients with serum IL-15 levels < or = 5 pg/ml showed significantly high rates of survival.
CONCLUSION: IL-15 is related to the pathogenesis of IP, HPS, and/or vasculitis. Serum IL-15 level could possibly be used as a marker of prognosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11708407

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  10 in total

Review 1.  Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.

Authors:  Wanlong Wu; Li Guo; Yakai Fu; Kaiwen Wang; Danting Zhang; Wenwen Xu; Zhiwei Chen; Shuang Ye
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-06       Impact factor: 8.667

2.  The distinct expressions of interleukin-15 and interleukin-15 receptor α in Behçet's disease.

Authors:  Jung-Yoon Choe; Hwajeong Lee; Sang Gyung Kim; Min Ji Kim; Sung-Hoon Park; Seong-Kyu Kim
Journal:  Rheumatol Int       Date:  2013-02-17       Impact factor: 2.631

Review 3.  Pathogenesis of dermatomyositis: role of cytokines and interferon.

Authors:  Lily Kao; Lorinda Chung; David F Fiorentino
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

Review 4.  Pathogenesis, classification and treatment of inflammatory myopathies.

Authors:  Mei Zong; Ingrid E Lundberg
Journal:  Nat Rev Rheumatol       Date:  2011-04-05       Impact factor: 20.543

5.  Enhanced development of functional human NK cells in NOD-scid-IL2rgnull mice expressing human IL15.

Authors:  Ken-Edwin Aryee; Lisa M Burzenski; Li-Chin Yao; James G Keck; Dale L Greiner; Leonard D Shultz; Michael A Brehm
Journal:  FASEB J       Date:  2022-09       Impact factor: 5.834

6.  Interleukin 15 levels in serum may predict a severe disease course in patients with early arthritis.

Authors:  Isidoro González-Álvaro; Ana M Ortiz; José María Alvaro-Gracia; Santos Castañeda; Belen Díaz-Sánchez; Inmaculada Carvajal; J Alberto García-Vadillo; Alicia Humbría; J Pedro López-Bote; Esther Patiño; Eva G Tomero; Esther F Vicente; Pedro Sabando; Rosario García-Vicuña
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

7.  Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity.

Authors:  Pawel Mielnik; Hanna Chwalinska-Sadowska; Ewa Wiesik-Szewczyk; Wlodzimierz Maslinski; Marzena Olesinska
Journal:  Rheumatol Int       Date:  2010-12-04       Impact factor: 2.631

8.  Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease.

Authors:  Dirk M Wuttge; Marie Wildt; Pierre Geborek; Frank A Wollheim; Agneta Scheja; Anita Akesson
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

9.  Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension.

Authors:  Rajeev Malhotra; Samuel Paskin-Flerlage; Roham T Zamanian; Patrick Zimmerman; Jonathan W Schmidt; Donna Y Deng; Mark Southwood; Robert Spencer; Carol S Lai; William Parker; Richard N Channick; Nicholas W Morrell; C Gregory Elliott; Paul B Yu
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

Review 10.  Interleukin-15 and cancer: some solved and many unsolved questions.

Authors:  Piera Filomena Fiore; Sabina Di Matteo; Nicola Tumino; Francesca Romana Mariotti; Gabriella Pietra; Selene Ottonello; Simone Negrini; Barbara Bottazzi; Lorenzo Moretta; Erwan Mortier; Bruno Azzarone
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.